October 2004 in “Australian Prescriber” Lifestyle changes are more effective than medication for reducing type 2 diabetes risk.
128 citations
,
March 1996 in “Journal of Investigative Dermatology” 54 citations
,
May 2015 in “Endocrinology” Manipulating 5α-reductase type 2 can affect liver fat production and glucocorticoid effects.
1 citations
,
January 2025 in “ARC Journal of Dermatology” July 2025 in “Indian Dermatology Online Journal” Switching insulin brands caused skin lesions in a diabetic woman, resolved by changing to oral medication.
15 citations
,
January 2024 in “Chemical Engineering Journal” 1 citations
,
November 2025 in “Neuro-Oncology” Safusidenib erbumine shows promise as a treatment for certain brain tumors, but mild side effects like hair loss need attention.
16 citations
,
September 1999 in “Journal of Investigative Dermatology Symposium Proceedings” 4 citations
,
December 2024 in “European Journal of Medicinal Chemistry” New pyrazole-based inhibitors show promise for treating metabolic diseases and other conditions.
6 citations
,
May 1986 in “Cancer Chemotherapy and Pharmacology” The drug TGU was ineffective against small cell lung cancer and caused significant bone marrow suppression.
May 2025 in “Journal of the ASEAN Federation of Endocrine Societies” Early advanced therapies are crucial for better survival in aggressive insulinoma cases.
11 citations
,
March 2019 in “Journal of Medicinal Chemistry” Some synthetic carbohydrate receptors, especially compounds 3 and 15, show strong potential for treating Zika virus.
April 2026 in “Research Square” Dapagliflozin helps protect heart cells under stress by improving mitochondrial function and reducing cell damage.
February 2025 in “medRxiv (Cold Spring Harbor Laboratory)” GLP-1 agonists may increase the risk of hair loss.
22 citations
,
May 2011 in “European Journal of Cancer” The drug combination was safe and showed promise in treating advanced tumors.
9 citations
,
May 2021 in “Molecules” New indole-based compounds, particularly cemtirestat, show promise as dual-function drugs for diabetic complications.
August 2025 in “Endokrynologia Polska”
1 citations
,
November 2020 in “Journal of The American Academy of Dermatology” GSK-36 downregulation with UTMD improves plaque stability in atherosclerosis treatment.
October 2004 in “Australian Prescriber” Lifestyle changes are more effective than metformin for reducing type 2 diabetes risk.
June 2023 in “Italian Journal of Medicine” Urotensin II increases growth and VEGF production in rat skin cells by turning on the Wnt-β-catenin pathway.
July 2024 in “Russian Journal of Child Neurology” Selumetinib effectively reduces tumor size in many children with neurofibromatosis type 1, but can cause skin and hair issues.
May 2024 in “International journal of medicine and psychology.” Yuperio combined with bisoprolol improves heart function in patients with dilated cardiomyopathy.
59 citations
,
August 2021 in “Frontiers in Endocrinology” GLP-1 receptor agonists, like Dulaglutide, Liraglutide, and Semaglutide, have potential benefits beyond the pancreas, including neuroprotection, pain suppression, cardiovascular protection, obesity management, and cancer treatment, but there are concerns about pancreatitis and pancreatic cancer risks.
December 2023 in “Journal of the Endocrine Society” Blocking glucocorticoid receptors improves glucose metabolism in a PCOS mouse model.
March 2023 in “The Journal of Urology” Higher SRD5A2 expression predicts better response to finasteride in treating urinary symptoms.
4 citations
,
December 1962 in “European journal of endocrinology” Alloxan diabetes, methylthiouracil, cortisone, and adrenaline affect how white mice hair follicles use glucose and cystine and their cell division.
6 citations
,
November 2004 in “Bioorganic & Medicinal Chemistry Letters” Scientists created iodinated arylhydantoins and arylthiohydantoins that could potentially be used for imaging prostate cancer. Some versions with specific side-chains showed high potential for this use.
4 citations
,
January 2011 Phenylpropanoid sucrose esters show potential as anticancer agents.
1 citations
,
May 1992 in “Pharmacological Research” March 2009 in “European Urology Supplements”